TP53 and cancer: The efficacy and safety of APR-246 to treat malignant tumors were evaluated in a phase 1 clinical trial, the first-in-human trial for mutp53-targeting drugs (NCT00900614), showing the upregulation of p53 target genes with good safety, tolerance, and PK properties.